ASSET OVERVIEW
A closer look at the opportunity.
Best-in-Class Potential for SCLC & NET
High affinity, selectivity, and internalization for superior tumor targeting.
Next-Gen Molecular Design
Novel TOPO-1 inhibitor payload, stable cysteine conjugation, and hydrophilic cleavable linker for enhanced efficacy & safety.
Strong Preclinical Data
Superior anti-tumor activity vs. ROVA-T, FZ-AD005, and other DLL3-ADCs, with a favorable safety profile.
Development Stage
IND Filing submitted, and Phase I study is expected in 2025Q1.
Large Market Opportunity
Addressing a $16.3B+ growing market with high unmet need in SCLC and neuroendocrine tumors (NET).
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities